Evaluation effect of Viola odorata vaginal suppository on the treatment of vaginal atrophy in post menopausal women

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220814055687N1

Enrollment

Registered

2022-09-04

Start date

2022-08-24

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaginal Atrophy. Postmenopausal atrophic vaginitis

Interventions

Intervention 1: Intervention group: Viola odorata vaginal suppository ,one suppository every night for 8 weeks.This suppository contains flavonoids, mucilage, saponin and a protein called cyclotide. T

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Women who had natural menopause confirmed by amenorrhea for one year or increased follicle stimulation hormone FSH>40 IU/I Having at least two symptoms from the descriptive evaluation table of the vaginal mucosa Women who are sexually active being married Women who are literate Phone number for follow up

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Subjective symptoms of vaginal atrophy. Timepoint: Before intervention. 4 and 8 weeks after the treatment. Method of measurement: Likert self-assessment scale.;Vaginal Maturation Value. Timepoint: Before intervention and 8 weeks after treatment. Method of measurement: Vaginal smear.;Vaginal PH. Timepoint: Before intervention, 8 weeks after treatment. Method of measurement: Litmus paper.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFataneh Amindehghan

Ardabil University of Medical Sciences

f.amindehghan@arums.ac.ir+98 21 7729 2107

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026